GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » EPS (Diluted)

Alere (ALRPRB.PFD) EPS (Diluted) : $0.00 (TTM As of Jun. 2017)


View and export this data going back to 2008. Start your Free Trial

What is Alere EPS (Diluted)?

Alere's Earnings per Share (Diluted) for the three months ended in Jun. 2017 was $0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 was $0.00.

Alere's EPS (Basic) for the three months ended in Jun. 2017 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2017 was $0.00.

Alere's EPS without NRI for the three months ended in Jun. 2017 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2017 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Alere EPS (Diluted) Historical Data

The historical data trend for Alere's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere EPS (Diluted) Chart

Alere Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alere Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alere's EPS (Diluted)

For the Diagnostics & Research subindustry, Alere's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alere's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Alere's PE Ratio distribution charts can be found below:

* The bar in red indicates where Alere's PE Ratio falls into.



Alere EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Alere's Diluted EPS for the fiscal year that ended in Dec. 2016 is calculated as

Diluted EPS (A: Dec. 2016 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-137.619-21.35)/0
=

Alere's Diluted EPS for the quarter that ended in Jun. 2017 is calculated as

Diluted EPS (Q: Jun. 2017 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-93.068-5.308)/0
=

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alere  (NYSE:ALRPRB.PFD) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Alere EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Alere's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Alere (ALRPRB.PFD) Business Description

Traded in Other Exchanges
N/A
Address
Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.
Executives
John Bridgen officer: Sr VP, Business Development 51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri officer: Senior VP, Global R&D 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell officer: Senior VP, Global Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers director C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant officer: VP, Controller, CAO 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan officer: SVP, Global Quality & Reg. 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp officer: Global Pres., Cardiometabolic 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani officer: Global Pres., Toxicology 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt director 51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon officer: SVP, Global Human Resources 4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy director C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453

Alere (ALRPRB.PFD) Headlines

From GuruFocus

Shareholders Approve Alere, Abbott Merger

By Alberto Abaterusso Alberto Abaterusso 07-10-2017

John Keeley Discloses Top New Stock Buys of Q2

By Holly LaFon Holly LaFon 09-17-2014

Watsa Buys 19 Holdings in What He Calls 'Stock-Picker's Market'

By Holly LaFon Holly LaFon 11-14-2017

Diamond Hill Select Fund Third Quarter 2014 Commentary

By Vera Yuan Vera Yuan 10-17-2014

5 Resilient Biotech Stocks to Buy for 2012

By Vatalyst.com Vatalyst.com 02-28-2012

Alere Reaches Settlement With SEC

By Alberto Abaterusso Alberto Abaterusso 09-29-2017

Alere Inc.: Foreign Currency Translations and the Euro

By Carmine Romano Carmine Romano 12-21-2011

Mario Gabelli's Asset Fund Q3 2014 Commentary

By Vera Yuan Vera Yuan 11-21-2014

Alere's Shareholders Approve Merger With Abbott

By Alberto Abaterusso Alberto Abaterusso 10-23-2016